Docality.com Logo
 
Dr. Nandini  Shah  Md image

Dr. Nandini Shah Md

9555 76Th Street
Pleasant Prairie WI 53158
262 778-8300
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 35252
NPI: 1639103716
Taxonomy Codes:
207Q00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

None Found

Publications

Second-generation compound for the modulation of utrophin in the therapy of DMD. - Human molecular genetics
Duchenne muscular dystrophy (DMD) is a lethal, X-linked muscle-wasting disease caused by lack of the cytoskeletal protein dystrophin. There is currently no cure for DMD although various promising approaches are progressing through human clinical trials. By pharmacologically modulating the expression of the dystrophin-related protein utrophin, we have previously demonstrated in dystrophin-deficient mdx studies, daily SMT C1100 treatment significantly reduced muscle degeneration leading to improved muscle function. This manuscript describes the significant disease modifying benefits associated with daily dosing of SMT022357, a second-generation compound in this drug series with improved physicochemical properties and a more robust metabolism profile. These studies in the mdx mouse demonstrate that oral administration of SMT022357 leads to increased utrophin expression in skeletal, respiratory and cardiac muscles. Significantly, utrophin expression is localized along the length of the muscle fibre, not just at the synapse, and is fibre-type independent, suggesting that drug treatment is modulating utrophin transcription in extra-synaptic myonuclei. This results in improved sarcolemmal stability and prevents dystrophic pathology through a significant reduction of regeneration, necrosis and fibrosis. All these improvements combine to protect the mdx muscle from contraction induced damage and enhance physiological function. This detailed evaluation of the SMT C1100 drug series strongly endorses the therapeutic potential of utrophin modulation as a disease modifying therapeutic strategy for all DMD patients irrespective of their dystrophin mutation.© The Author 2015. Published by Oxford University Press.

Map & Directions

9555 76Th Street Pleasant Prairie, WI 53158
View Directions In Google Maps

Nearby Doctors

9555 76Th St
262 778-8300
9555 76Th Street
262 778-8300
9555 76Th Street
262 778-8300
9555 76Th St Suite 4106
262 535-5437
9555 76Th St Suite 4105
262 778-8080
9555 76Th Street
262 562-2273
9555 76Th St Suite 2602
262 778-8400
9555 76Th St
414 906-6720
9555 76Th Street
262 778-8300